American Society for Gastrointestinal Endoscopy Includes WATS3D in Its New Practice Guideline for the Screening and Surveillance of Barrett’s Esophagus

 

SUFFERN, N.Y., (GLOBE NEWSWIRE), September 4, 2019 — CDx Diagnostics®, developer of the WATS3D diagnostic platform for the screening and surveillance of Barrett’s esophagus (BE), a known precursor to esophageal cancer (EC), today announced that the American Society for Gastrointestinal Endoscopy (ASGE) has included WATS3D in its Standards of Practice Committee’s guideline for the screening and surveillance of BE.

"It is our hope that broader use of WATS3D can potentially transform EC into a preventable disease. I would like to thank the physicians who have participated in our clinical studies for their guidance and dedication as well as the CDx team led by Dr. Mark Rutenberg for enabling us to reach this pivotal milestone today," said William Huffnagle, CEO of CDx Diagnostics.

GLOBE NEWSWIRE, September 4, 2019

Read the Press Release >

 

Get the latest posts in your email.

icon-support

Support

If you’re looking for more information about our products and services or have a general question,
we are here to help.

Request Support

icon-pathology-partnership

Pathology Partnership Program

Join our network of pathologists to help provide access to WATS3D diagnostics to patients around the world.

Learn More

icon-physician-finder

Physician Finder

We’ve created a convenient tool to help you find healthcare providers near you that use CDx testing.

Search Now